Maturation of Human Embryonic Stem Cell–Derived Pancreatic Progenitors Into Functional Islets Capable of Treating Pre-existing Diabetes in Mice
- Alireza Rezania1,
- Jennifer E. Bruin2,
- Michael J. Riedel2,
- Majid Mojibian2,
- Ali Asadi2,
- Jean Xu1,
- Rebecca Gauvin1,
- Kavitha Narayan1,
- Francis Karanu1,
- John J. O’Neil1,
- Ziliang Ao3,
- Garth L. Warnock3 and
- Timothy J. Kieffer2,3
- 1BetaLogics Venture, Janssen Research and Development, LLC, Raritan, New Jersey
- 2Laboratory of Molecular and Cellular Medicine, Department of Cellular and Physiological Sciences, Life Sciences Institute, University of British Columbia, Vancouver, British Columbia, Canada
- 3Department of Surgery, University of British Columbia, Vancouver, British Columbia, Canada
- Corresponding author: Timothy J. Kieffer, , or Alireza Rezania, .
A.R. and J.E.B. contributed equally to this work.
Diabetes is a chronic debilitating disease that results from insufficient production of insulin from pancreatic β-cells. Islet cell replacement can effectively treat diabetes but is currently severely limited by the reliance upon cadaveric donor tissue. We have developed a protocol to efficiently differentiate commercially available human embryonic stem cells (hESCs) in vitro into a highly enriched PDX1+ pancreatic progenitor cell population that further develops in vivo to mature pancreatic endocrine cells. Immature pancreatic precursor cells were transplanted into immunodeficient mice with streptozotocin-induced diabetes, and glycemia was initially controlled with exogenous insulin. As graft-derived insulin levels increased over time, diabetic mice were weaned from exogenous insulin and human C-peptide secretion was eventually regulated by meal and glucose challenges. Similar differentiation of pancreatic precursor cells was observed after transplant in immunodeficient rats. Throughout the in vivo maturation period hESC-derived endocrine cells exhibited gene and protein expression profiles that were remarkably similar to the developing human fetal pancreas. Our findings support the feasibility of using differentiated hESCs as an alternative to cadaveric islets for treating patients with diabetes.
This article contains Supplementary Data online at http://diabetes.diabetesjournals.org/lookup/suppl/doi:10.2337/db11-1711/-/DC1.
M.J.R. is currently affiliated with STEMCELL Technologies, Vancouver, British Columbia, Canada.
- Received January 23, 2012.
- Accepted May 19, 2012.
- © 2012 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.